Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
25 oct. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
11 oct. 2022 07h00 HE
|
NMD Pharma
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Data provides first clinical proof of the mechanism of action of NMD Pharma’s...
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
11 oct. 2022 01h00 HE
|
NMD Pharma
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Data provides first clinical proof of the mechanism of action of NMD Pharma’s...
Intravenous Immunoglobulin Market to Advance at CAGR of 7.3% During 2022–2031: TMR Study
30 mai 2022 06h30 HE
|
Transparency Market Research
Albany NY, United States, May 30, 2022 (GLOBE NEWSWIRE) -- The global market for intravenous immunoglobulin is prospering from the steady adoption of products in the treatment of a wide range of...
Myasthenia Gravis Treatment Market Size [2022-2029]: $2.03 Billion by 2028 at CAGR of 7.5%
26 mai 2022 06h26 HE
|
Fortune Business Insights
Pune, India, May 26, 2022 (GLOBE NEWSWIRE) -- The global myasthenia gravis treatment market size is anticipated to reach USD 2.03 billion by 2028 and exhibit a CAGR of 7.5% during the forecast...
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®
11 mars 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
BrightInsight and UCB Partner to Build Digital Care Solutions for Rare Diseases
08 mars 2022 08h30 HE
|
BrightInsight
SAN JOSE, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today a...
Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies
08 mars 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022
03 mars 2022 09h20 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Myasthenia Gravis Treatment Market Size [2022-2028] worth USD 2.03 billion | Exhibit a CAGR of 7.5%
28 févr. 2022 08h14 HE
|
Fortune Business Insights
Pune, India, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The global myasthenia gravis treatment market size is anticipated to reach USD 2.03 billion by 2028 and exhibit a CAGR of 7.5% during the forecast...